Smarter Genomics.
Faster Insights. Greater Confidence.
AI-powered NGS bioinformatics
to drive personalized medicine forward.
Streamline germline and somatic analyses across panels, exomes, and genomes, supporting short and long-read sequencing. Our platform is wet lab and sequencer-agnostic, purpose-built for you.
Our DiagAI Score pinpoints the most relevant variants instantly, using advanced pathogenicity prediction, phenotype matching, and expert-driven rules—so you get clear, actionable results at lightning speed.
SeqOne Flow automates your entire data pipeline—from file transfer to analysis initiation. Integrated with LIMS and IT systems, it eliminates manual work, speeds up turnaround times, and keeps everything running smoothly.
Clinically validated. Premium annotation. Uncompromising precision. SeqOne integrates top-tier databases, including CKB and COSMIC, to deliver high-confidence insights, so you can make decisions with certainty.
We put our customers at the center of everything we do. SeqOne adapts to your needs—integrating your feedback and the latest genomics advancements to keep your workflows efficient, seamless, and always up to date.
Your data stays yours—never shared, never sold. Our patented double-encryption system secures each patient file with a unique key for maximum data protection. You stay safe, compliant, and in control.
The SeqOne Platform is an in vitro diagnostic medical device, CE-IVD Class C certified under IVDR. The company is certified under ISO 13485 for medical grade quality, ISO 27001-compliant, and HDS-certified for maximum data security.
Identify acquired mutations in cancers.
Pinpoint germline variants.
Validate SeqOne with your own data, expert support, and zero commitment.
Pay-per-analysis with no hidden fees or volume constraints.
Access field specialists, multi-lingual assistance and hands-on guidance.
A new partnership delivers end-to-end genome nanopore sequencing solutions for clinical applications in rare disease and oncology.
SeqOne launches HRD test for ovarian cancer patients, validated with PAOLA-1 cohort. Clinical validation shows comparable survival benefits to Myriad myChoice® CDx.
Professor Anne-Sophie Lèbre of CHU de Reims uses SeqOne for rare disease and oncology genomics, enabling rapid, precise variant interpretation.
SeqOne Platform gets IVDR Class C medical device certification for NGS analysis in oncology and rare diseases, validating quality and safety.
MGI and SeqOne partner to develop genomic analysis solutions, combining MGI's sequencing tech with SeqOne's AI-powered platform.
Martin Dubuc appointed as SeqOne Genomics CEO, Nicolas Philippe becomes President & CPSO to drive global clinical genomics expansion.
GenomeAlert! reevaluates genetic variant classifications monthly against ClinVar to ensure accurate patient diagnoses and treatment.
SeqOne Cloud now supports Agilent CGH MicroArrays, offering AI-powered CNV annotation, ACMG classification, and seamless Cartagenia migration.
APHM and SeqOne partner to automate exome sequencing with AI, processing up to 2,000 rare disease samples yearly for better diagnostics.
SeqOne’s HRD platform enables North West GLH to conduct in-house genomic instability testing for ovarian cancer.
DiagAI uses inheritance & quality rules based on real diagnostic data, enabling clinicians to understand AI recommendations and collaborate on system improvement.
